Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-25
DOI
10.1186/s12885-020-07654-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS
- (2020) Qiong Wang et al. Frontiers in Oncology
- Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
- (2019) Yukie Fujimoto et al. Breast Cancer
- Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy
- (2019) Anne-Sophie Hamy et al. CLINICAL CANCER RESEARCH
- Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
- (2018) Sung Gwe Ahn et al. BMC CANCER
- Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
- (2018) Mark O’Loughlin et al. BREAST CANCER RESEARCH AND TREATMENT
- TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes
- (2018) Franziska Würfel et al. Breast Care
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
- (2018) Michail Ignatiadis et al. JNCI-Journal of the National Cancer Institute
- Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
- (2018) Miao Ruan et al. Diagnostic Pathology
- Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy
- (2018) S J Luen et al. ANNALS OF ONCOLOGY
- A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
- (2018) Hye Won Hwang et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
- (2018) Xia Yang et al. Targeted Oncology
- The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
- (2017) Hitomi Mori et al. Oncotarget
- Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
- (2017) In Hye Song et al. Cancer Research and Treatment
- Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2016) Xiaoxian (Bill) Li et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial
- (2016) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
- (2016) Alexander S. Brodsky et al. BMC CANCER
- Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
- (2016) Giancarlo Pruneri et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
- (2016) B. Ingold Heppner et al. CLINICAL CANCER RESEARCH
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis
- (2015) Daqing Jiang et al. BMC CANCER
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
- (2013) Yasmin Issa-Nummer et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now